AMINOSYN-HF 8%

Post-LOE

amino acids

ICU Medical

ANDAINJECTIONINJECTABLE

Approved

Apr 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (16)

NCT07060040N/ANot Yet Recruiting

The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status

Started Jul 2025

100 enrolled

ESRD (End-Stage Renal Disease)Dialysis

NCT05935826Phase 3Recruiting

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Started Jun 2024

55 enrolled

Hepatic SteatosisNAFLDAdolescent Obesity

NCT05954923N/ACompleted

The Glucagonotropic Effect of Amino Acids in Humans

Started Sep 2023

12 enrolled

Healthy

NCT05174559N/AUnknown

Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)

Started Sep 2023

10 enrolled

Phenylketonurias

NCT04872530N/ACompleted

Bioavailability of Plant Protein Amino Acids

Started Jan 2020

10 enrolled

Bioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy Men

Worked on AMINOSYN-HF 8% at ICU Medical? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.